If the U.S. Treasury Department's newest tax proposal derails Pfizer Inc.'s $160 billion deal for Allergan Plc, it won't be the first time in recent history that the government has upended a record pharmaceutical acquisition with policies designed to block so-called tax inversions.
Source: Bloomberg Politics